A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.

Abstract:

:Graft-versus-host disease (GVHD) remains a major immunological complication after allogeneic bone marrow transplantation (allo-BMT), but also favors development of the beneficial graft-versus-leukemia (GVL) effect. A patient with AML-M4 (inv (16)) is described, who was given non-myeloablative remission reinduction therapy for leukemic relapse (inv (16), trisomy 8) diagnosed on day 184 after HLA-compatible sibling BMT. On day 236, ie about 6 weeks after completion of this course, a clinical syndrome suggestive of acute GVHD grade 3 had developed. Skin biopsy confirmed the clinical diagnosis of GVHD, with a compatible liver biopsy. Transfusion-associated GVHD was ruled out by analysis of short tandem repeat (STR) alleles in the skin biopsy, revealing alleles from donor and recipient but not from third party origin. Cyclosporin A (CsA) therapy, which had been tapered between days 150 and 175, was resumed, resulting in a favorable response and gradual transition to limited chronic GVHD. The patient has since remained in complete remission with an excellent performance status for more than 40 months, without further chemotherapy. Thus this biopsy proven case of GVHD was induced by marrow donor lymphocytes more than 200 days after transplantation and apparently triggered by remission reinduction chemotherapy. The case indicates that intensive non-myeloablative chemotherapy can cure AML relapsing after allo-BMT. The therapeutic effect in this case probably involved a direct pharmacological suppression of the leukemic clone followed by a GVL effect initiated by donor-derived alloreactive T lymphocytes.

journal_name

Leukemia

journal_title

Leukemia

authors

Vandenberghe P,Verhoef GE,Emonds MP,Demuynck H,Zachée P,De Wolf-Peeters C,Decorte R,Cassiman JJ,Boogaerts MA

doi

10.1038/sj.leu.2400810

subject

Has Abstract

pub_date

1997-10-01 00:00:00

pages

1775-8

issue

10

eissn

0887-6924

issn

1476-5551

journal_volume

11

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period.

    abstract::Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred and seventy-eight ALL patients, referred to our hospital from 1978 to 1999, were reviewed for long-term follo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402289

    authors: Thomas X,Danaïla C,Le QH,Sebban C,Troncy J,Charrin C,Lhéritier V,Michallet M,Magaud JP,Fiere D

    更新日期:2001-12-01 00:00:00

  • Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia.

    abstract::The efficacy of antifungal prophylaxis with itraconazole capsules and its serum concentrations were evaluated in patients intensively treated for acute leukaemia. A consecutive group of patients without systemic antifungal prophylaxis (January 1993 to August 1994, period 1) was compared with another consecutive group ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401137

    authors: Glasmacher A,Molitor E,Hahn C,Bomba K,Ewig S,Leutner C,Wardelmann E,Schmidt-Wolf IG,Mezger J,Marklein G,Sauerbruch T

    更新日期:1998-09-01 00:00:00

  • Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B.

    abstract::B-cell-specific plasma-membrane proteins are potential targets for either small molecule or antibody-based therapies. We have sought to annotate proteins expressed at the cell surface membrane in patients with chronic lymphocytic leukemia (CLL) using plasma-membrane-based proteomic analysis to identify previously unch...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402993

    authors: Boyd RS,Adam PJ,Patel S,Loader JA,Berry J,Redpath NT,Poyser HR,Fletcher GC,Burgess NA,Stamps AC,Hudson L,Smith P,Griffiths M,Willis TG,Karran EL,Oscier DG,Catovsky D,Terrett JA,Dyer MJ

    更新日期:2003-08-01 00:00:00

  • DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.

    abstract::Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.98

    authors: O'Leary HA,Capitano M,Cooper S,Mantel C,Boswell HS,Kapur R,Ramdas B,Chan R,Deng L,Qu CK,Broxmeyer HE

    更新日期:2017-11-01 00:00:00

  • Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

    abstract::Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.109

    authors: Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

    更新日期:2011-09-01 00:00:00

  • A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    abstract::A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2012.301

    authors: Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

    更新日期:2013-04-01 00:00:00

  • Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

    abstract::Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.298

    authors: Patnaik MM,Hanson CA,Hodnefield JM,Lasho TL,Finke CM,Knudson RA,Ketterling RP,Pardanani A,Tefferi A

    更新日期:2012-01-01 00:00:00

  • Detection of additional JH/BCL2 translocations in follicular lymphoma.

    abstract::In vitro enzymatic amplification and direct sequencing were used to detect and characterize t(14;18) recombination junctions in peripheral blood and bone marrow mononuclear cell preparations from patients with follicular lymphoma in remission. Samples from 24/44 patients were found to be positive for translocations in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Price CG,Tuszynski A,Watt SM,Murdoch SJ,Lister TA,Young BD

    更新日期:1991-07-01 00:00:00

  • Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.

    abstract::Previous studies demonstrated that triazene compounds (TZC) possess antitumor, antimetastatic and immunosuppressive activity, and induce novel antigenic properties in neoplastic cells. Moreover, TZC showed marked antitumor activity in patients with acute myelogenous leukemias (AML). In most cases leukemic blasts with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tentori L,Graziani G,Gilberti S,Lacal PM,Bonmassar E,D'Atri S

    更新日期:1995-11-01 00:00:00

  • Characterization of an interleukin-2 dependent human leukemic cell line, PER-315, with an immature T cell phenotype which does not express the tac antigen.

    abstract::Cell line PER-315 was established from a bone marrow sample of a 5-year-old boy diagnosed with acute lymphoblastic leukemia (ALL) of T cell lineage. PER-315 cells express the surface markers present on immature thymocytes, express cytoplasmic CD3, and their growth is dependent on interleukin-2 (IL-2). Hence, this cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kees UR,Ford J,Ranford PR,Dawson VM

    更新日期:1990-04-01 00:00:00

  • Leukemogenesis by the chromosomal translocations.

    abstract::The AML1 is the most commonly involved transcription factor gene in human leukemias and forms chimeric transcription factor genes, namely, AML1/MTG8 by the t(8;21), AML1/EVI-1 by the t(3;21), and TEL/AML1 by the t(12;21). The AML1a and AML1b, two isoforms of the AML1 protein, are translated from the AML1 gene by the a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Mitani K

    更新日期:1997-04-01 00:00:00

  • Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.

    abstract::Neutropenia-related fungal infections can be life-threatening despite antifungal therapy. We evaluated the role of recombinant granulocyte colony-stimulating factor (rG-CSF)-elicited white blood cell (WBC) transfusions in patients with neutropenia-related fungal infections. Adult patients with hematologic malignancies...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2400811

    authors: Dignani MC,Anaissie EJ,Hester JP,O'Brien S,Vartivarian SE,Rex JH,Kantarjian H,Jendiroba DB,Lichtiger B,Andersson BS,Freireich EJ

    更新日期:1997-10-01 00:00:00

  • Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.

    abstract::Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for M...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403263

    authors: Brüggemann M,van der Velden VH,Raff T,Droese J,Ritgen M,Pott C,Wijkhuijs AJ,Gökbuget N,Hoelzer D,van Wering ER,van Dongen JJ,Kneba M

    更新日期:2004-04-01 00:00:00

  • Cell-free transmission of Fv-4 resistance gene product controlling Friend leukemia virus-induced leukemogenesis in mice.

    abstract::Fv-4 is a mouse gene that dominantly confers resistance to infection by ecotropic murine leukemia virus (MuLV). The Fv-4' env antigen that binds to the cell surface of Fv-4'-bearing C3H cells was found in sera from normal Fv-4'-bearing C4W mice. The serum Fv-4' env antigen binds to ecotropic MuLV receptors, shown by s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kitagawa M,Aizawa S,Ikeda H,Hirokawa K

    更新日期:1997-04-01 00:00:00

  • NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

    abstract::In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10-15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are significantly overrepresented in trisomy 12 CLL, a disease subset frequently expressing CD49d, th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.296

    authors: Benedetti D,Tissino E,Pozzo F,Bittolo T,Caldana C,Perini C,Martorelli D,Bravin V,D'Agaro T,Rossi FM,Bomben R,Santinelli E,Zaja F,Pozzato G,Chiarenza A,Di Raimondo F,Del Poeta G,Rossi D,Gaidano G,Dal Bo M,Gattei V

    更新日期:2018-03-01 00:00:00

  • Risk score model for fatal intracranial hemorrhage in acute leukemia.

    abstract::To build a risk score (RS) model of fatal intracranial hemorrhage (FICH) in patients with acute leukemia, we retrospectively assessed risk factors in 792 patients newly diagnosed with acute leukemia, 41 of whom had analyzable FICH. We found that female gender (relative risk (RR) = 5.234, P<0.001), acute promyelocytic ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404148

    authors: Kim H,Lee JH,Choi SJ,Lee JH,Seol M,Lee YS,Kim WK,Lee JS,Lee KH

    更新日期:2006-05-01 00:00:00

  • Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

    abstract::Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), bu...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2015.143

    authors: Pigneux A,Labopin M,Maertens J,Cordonnier C,Volin L,Socié G,Blaise D,Craddock C,Milpied N,Bacher U,Malard F,Esteve J,Nagler A,Mohty M,Acute Leukemia Working Party EBMT.

    更新日期:2015-12-01 00:00:00

  • Stroma-conditioned media improve expansion of human primitive hematopoietic stem cells and progenitor cells.

    abstract::It has been reported that stroma-dependent cultures support proliferation of hematopoietic stem cells (HSC). In order to investigate the effect of soluble stromal factors, we developed short-term serum-low liquid cultures in which the effect of stroma-conditioned media (SCM) from the murine FBMD-1, and human L87/4 and...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400530

    authors: Breems DA,Blokland EA,Ploemacher RE

    更新日期:1997-01-01 00:00:00

  • Myeloid differentiation antigens identify leukemic cell subpopulations with different cell cycle characteristics.

    abstract::In order to assess the proliferative capacity of leukemic subpopulations and to know whether it can be related to the stage of maturation, the expression of two surface antigens identifying distinct steps of leukocyte differentiation (CD15 and CD34) was studied by flow cytometry in correlation with DNA content in 16 c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Campos L,Ffrench M,Guyotat D

    更新日期:1990-01-01 00:00:00

  • Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

    abstract::In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.375

    authors: Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

    更新日期:2014-06-01 00:00:00

  • Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

    abstract::Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.183

    authors: Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

    更新日期:2017-01-01 00:00:00

  • Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

    abstract::The outcome of a cohort of 218 consecutive patients who failed to respond to a single course of standard daunorubicin plus ARAC (three + seven) induction regimen has been retrospectively evaluated to assess the characteristics of this group of AML patients and the effectiveness of second-line induction programs. Seven...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Liso V,Iacopino P,Avvisati G,Petti MC,Broccia G,Carotenuto M,Falda M,Fazi P,Lazzarino M,Leoni P,Mirto S,Pucci G,Nobile F,Nosari AM,Specchia G,Stasi R,Tabilio A,Mandelli F

    更新日期:1996-09-01 00:00:00

  • Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

    abstract::Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404681

    authors: Jiménez M,Ercilla G,Martínez C

    更新日期:2007-08-01 00:00:00

  • Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

    abstract::Activation of the MEK/ERK/MAP kinase signaling pathway promotes the proliferation and survival of hematopoietic cells. The kinases MEK-1, MEK-2, ERK-1/MAPK and ERK-2/MAPK are activated by phosphorylation at specific sites, and these events can be monitored using phospho-specific antibodies. In this report we examined ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402400

    authors: Miranda MB,McGuire TF,Johnson DE

    更新日期:2002-04-01 00:00:00

  • Mast cell growth factor, a ligand for the receptor encoded by c-kit, affects the growth in culture of the blast cells of acute myeloblastic leukemia.

    abstract::The c-kit proto-oncogene encodes a transmembrane receptor with a tyrosine kinase internal domain. C-kit has been mapped to the W locus in the mouse, and the gene encoding the ligand has been shown to be the product of the murine SI locus. Previous genetic studies have shown that the murine W and SI loci play important...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wang C,Koistinen P,Yang GS,Williams DE,Lyman SD,Minden MD,McCulloch EA

    更新日期:1991-06-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405014

    authors: de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期:2008-02-01 00:00:00

  • A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

    abstract::This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.34

    authors: Brandwein JM,Hedley DW,Chow S,Schimmer AD,Yee KW,Schuh AC,Gupta V,Xu W,Kamel-Reid S,Minden MD

    更新日期:2011-06-01 00:00:00

  • A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

    abstract::Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.194

    authors: Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

    更新日期:2008-10-01 00:00:00

  • Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.

    abstract::B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5(+) B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404185

    authors: Mous R,Savage P,Remmerswaal EB,van Lier RA,Eldering E,van Oers MH

    更新日期:2006-06-01 00:00:00

  • RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

    abstract::In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.274

    authors: Chanut A,Duguet F,Marfak A,David A,Petit B,Parrens M,Durand-Panteix S,Boulin-Deveza M,Gachard N,Youlyouz-Marfak I,Bordessoule D,Feuillard J,Faumont N

    更新日期:2014-04-01 00:00:00